Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241612588 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Feng-Lung Tsai und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Colorectal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council of Taiwan.
Abstract (Originalsprache)
Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies and a leading cause of cancer worldwide. Histone deacetylases (HDACs), which regulate cell proliferation and survival, are associated with the development and progression of cancer. Moreover, HDAC inhibitors are promising therapeutic targets, with five HDAC inhibitors approved for cancer treatment to date. However, their safety profile necessitates the exploration of well-tolerated HDAC inhibitors that can be used in cancer therapeutic strategies. In this study, the pan-HDAC inhibitor MPT0G236 reduced the viability and inhibited the proliferation of human colorectal cancer cells, and normal human umbilical vein endothelial cells (HUVECs) showed reduced sensitivity. These findings indicated that MPT0G236 specifically targeted malignant tumor cells. Notably, MPT0G236 significantly inhibited the activities of HDAC1, HDAC2, and HDAC3, Class I HDACs, as well as HDAC6, a Class IIb HDAC, at low nanomolar concentrations. Additionally, it promoted the accumulation of acetyl-α-tubulin and acetyl-histone H3 in HCT-116 and HT-29 cells in a concentration-dependent manner. Furthermore, MPT0G236 treatment induced G2/M cell cycle arrest in CRC cells by initially regulating the levels of cell-cycle-related proteins, such as p-MPM2; specifically reducing p-cdc2 (Y15), cyclin B1, and cdc25C levels; and subsequently inducing apoptosis through the caspase-dependent pathways and PARP activation. Our findings demonstrate that MPT0G236 exhibits significant anticancer activity in human colorectal cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
- TMU Research Center for Drug Discovery, Taipei Medical University, Taipei 110, Taiwan.
- Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan.
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan.
- Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan.
- TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 110, Taiwan.
ORCID-Profile: Chia-Ron Yang
Förderung
- National Science and Technology Council of Taiwan
Zitieren
APA
Tsai, F. L., Huang, H. L., Lai, M. J., Liou, J. P., Pan, S. L., & Yang, C. R. (2023). Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241612588
Vancouver
Tsai FL, Huang HL, Lai MJ, Liou JP, Pan SL, Yang CR. Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241612588
BibTeX
@article{Tsai2023,
author = {Tsai, Feng-Lung and Huang, Han-Li and Lai, Mei-Jung and Liou, Jing-Ping and Pan, Shiow-Lin and Yang, Chia-Ron},
title = {Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241612588}
}
EUVIMED